Most investors would like a "do over."

They look back on certain investments and wish they'd never heard of, much less put money in them. Sure things like your good friend's invention that would make beer in one day from water and weeds. Or your brother's idea of selling real estate on Saturn. Everyone has their own stories. Mine are usually related to private investments in the medical device field or biotech, though I did have one out of Florida that made a "pig" that ran through oil pipelines to check on their safety. After meeting the founder who looked more like a used car salesman that caught a great sale on polyester suits, I should have known better right then. But I didn't.

Analyst Upgrades

• Polo Ralph Lauren (RL) to buy from hold at Citigroup.
• Qualcomm (QCOM) to buy from neutral at Roth Capital.
• Walgreen (WAG) to conviction buy from neutral at Goldman.
• Rockwell (ROK) to outperform from neutral at Credit Suisse.
• Carnival (CCL) to buy from hold at Deutsche Bank.
• SunTrust (STI) and TD Bank (TD) to outperform from market perform at Keefe Bruyette.
• Hawaiian Electric (HE) to outperform from neutral at RW Baird.
• Essex Property Trust (ESS) to outperform from neutral at Macquarie.
• Amgen (AMGN) to neutral from underperform at BofA/Merrill.

Late Monday, Amgen (AMGN) unveiled positive results for its bone drug, denosumab. A clinical study of 1,432 men with hormone refractory prostate cancer revealed that denosumab, which is also known as Xgeva, improved bone metastasis-free survival by 4.2 months. However, the overall survival rate was comparable to a placebo group.

Denosumab is already used to treat osteoporosis under the brand name Prolia, and has been approved under the brand name Xgeva for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. The drug has not yet been approved for the prevention of SREs in multiple myeloma patients.

Analyst Upgrades

• Amgen (AMGN) to overweight from neutral at Piper Jaffray.
• Goodrich Petroleum (GDP) to outperform from market perform at Wells Fargo.
• Tutor Perini (TPC) to buy from neutral at UBS.
• Covidien (COV) to buy from neutral at Goldman.
• Sara Lee (SLE) and Comcast (CMCSA) to outperform from market perform at Bernstein.
• Research In Motion (RIMM) to outperform from sector perform at FBN Securities.

Analyst Upgrades

• Goldman upgraded Jones Lang LaSalle (JLL) to buy from neutral.
• Credit Suisse upgraded Pulte Group (PHM) to neutral from underperform. Note that Citigroup downgraded the stock.
• Ameristar Casinos (ASCA) was upgraded to neutral from sell at Merriman.
• Citigroup upgraded Kimco Realty (KIM) to hold from sell.
• Mistras (MG) was upgraded to buy from hold at KeyBanc.
• Devon Energy (DVN) was upgraded to outperform from neutral at Macquarie.
• Garmin (GRMN) was upgraded to outperform from sector perform at PacCrest.

Analyst Upgrades

• Soleil upgraded Hologic (HOLX) to buy from hold on expectations the company's next-generation breast tomosynthesis instrument is likely to receive FDA approval. The firm raised its target price for shares to $20 from $16.
• ING Group upgraded Total (TOT) to buy from hold.
• BofA/Merrill raised Medicis (MRX) to neutral from underperform.
• CPFL Energia (CPL) was upgraded to buy from hold at Deutsche Bank.

Shares of biotech giant Amgen, Inc. (AMGN) are trading slightly higher in after hours trading this afternoon after the company delivered better than expected earnings for its second quarter.

Going into this afternoon's earnings report, analysts had been expecting to see Amgen report $1.30 per share, but the company was able to beat out analyst estimates by reporting an actual $1.38 for the quarter.

Health care stocks are seen as low-risk investments by many stock market investors. After all – folks will always get sick, right? While that may be the case, it's an oversimplification to say that all health care stocks then have a built in customer base. The fact of the matter is that the health care industry has seen a big shakeup in the wake of Obama's health care reform bill and not all stocks in this sector are adapting well.

To keep your portfolio in perfect health, here are three big-name health care blue chips to sell now.

Amgen (AMGN - option chain) shares are rising today after the company said this morning the Food and Drug Administration has agreed to a priority review for Denosumab, its new skeletal drug. The FDA will decide whether to approve the drug by November 18. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on AMGN.

AMGN opened this morning at $52.46. So far today the stock has hit a low of $50.32 and a high of $64.76. As of 12:15, AMGN is trading at $53.00 up 0.83 (1.6%). The chart for AMGN looks bullish and S&P gives AMGN a positive 4 STARS (out of 5) buy ranking.

It appears that financial institutions, drug makers and oil companies have caught the attention of traders today -- at least, that's what they're searching for.

If you want to know what stocks traders are interested in right now at this very second, you need look no further than what's hot in Google.

Here's what's hot today.

Amgen (AMGN - option chain) shares are rising today after the Food & Drug Administration granted approval for its osteoporosis treatment Prolia two months earlier than expected. The company forecast revenue from the treatment of $115 million in 2010, $862 million in 2011, and $2.4 billion for 2013. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on AMGN.

AMGN opened this morning at $53.55. So far today the stock has hit a low of $53.31 and a high of $55.35. As of 12:30, AMGN is trading at $55.05 up $4.29 (8.5%). The chart for AMGN looks bullish and S&P gives AMGN a positive 4 STARS (out of 5) buy ranking.

A lot of investors think Amgen (AMGN) is a great next-generation biotech company. Wrong. Amgen was a decent last-generation biotech company.

It's terribly managed outfit living on EPO drugs for dialysis and oncology patients. True, it has a billion dollar (actually more) drug, Neupogen, but it could be subject to generic competition in the United States from TEVA within two years.

Spring is finally here, which means it's time to break out the broom and dustpan for some spring cleaning.

But your home isn't the only thing that requires constant maintenance -- your portfolio does too.

And what better time than spring to get a fresh start by cleaning out the stocks that are sitting around collecting dust rather than making you money?

Amgen Inc. (AMGN) announced this morning that its board of directors has authorized an additional stock buyback of up to $5 billion. The newly approved program adds to AMGN's existing share repurchase plan of roughly $1.2 billion. "This new authorization reflects Amgen's confidence in its long-term prospects," said the biotech firm in a press release.

Apparently, AMGN's confidence is not contagious, with the stock trading fractionally lower at last check. In fact, the stock is now hovering below short-term support from its 10-day moving average, which has been breached only once on a daily closing basis since early November.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• Amgen Inc. (NASDAQ: AMGN) reported strong Q2 earnings thought revenue fell but beat analysts' estimates.
• Colgate-Palmolive Co. (NYSE: CL) beat Q2 earnings estimates but revenue suffered from currency effects.
• Dow Chemical Co. (NYSE: DOW) reported a drop in Q2 revenue and a net loss on restructuring charges.
• Eastman Kodak Co. (NYSE: EK) posted a deeper-than-expected Q2 net loss as sales plunged.
• Exxon Mobil Corp. (NYSE: XOM) reported its lowest quarterly profit in years, well short of expectations.